Role of prostate dose escalation in patients with greater than 15% risk of pelvic lymph node involvement

This publication has 21 references indexed in Scilit:

• Prostate Cancer Radiotherapy Dose Response: An Update of the Fox Chase Experience
  Journal of Urology, 2004
• Phase III Trial of Long-Term Adjuvant Androgen Deprivation After Neoadjuvant Hormonal Cytoreduction and Radiotherapy in Locally Advanced Carcinoma of the Prostate: The Radiation Therapy Oncology Group Protocol 92–02
  Journal of Clinical Oncology, 2003
• Improved Biochemical Disease-Free Survival of Men Younger Than 60 Years With Prostate Cancer Treated With High Dose Conformal External Beam Radiotherapy
  Journal of Urology, 2003
• Phase III Trial Comparing Whole-Pelvic Versus Prostate-Only Radiotherapy and Neoadjuvant Versus Adjuvant Combined Androgen Suppression: Radiation Therapy Oncology Group 9413
  Journal of Clinical Oncology, 2003
• Dose response in prostate cancer with 8–12 years’ follow-up
  International Journal of Radiation Oncology*Biology*Physics, 2002
• Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin
  New England Journal of Medicine, 1997
• Androgen suppression plus radiation versus radiation alone for patients with D1 (pN+) adenocarcinoma of the prostate (results based on a national prospective randomized trial, RTOG 85-31)
  International Journal of Radiation Oncology*Biology*Physics, 1997
• Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and gleason score in men with clinically localized prostate cancer
  International Journal of Radiation Oncology*Biology*Physics, 1994
• Radiation therapy in prostate cancer: Whole pelvis with prostate boost or small field to prostate?
  Urology, 1992
• Nonparametric Estimation from Incomplete Observations
  Journal of the American Statistical Association, 1958